The FASEB Journal, Vol 10, 1014-1024, Copyright © 1996 by The Federation of American Societies for Experimental Biology

REVIEWS

Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta- glucuronide

F Formelli, AB Barua and JA Olson
Istituto Nazionale per lo Studio e la Cura dei Tumori, Division of Experimental Oncology, Milan, Italy.

N-(4-Hydroxyphenyl) retinamide (4HPR) and retinoyl beta-glucuronide (RAG) are two derivatives of all-trans retinoic acid (RA) that show properties both similar to as well as different from their parent compound, RA. Both retinoids possess the important property of showing much-reduced toxicity relative to RA while maintaining significant biological activity. 4HPR, a synthetic derivative, is active in the prevention and treatment of a variety of neoplasms in animals, and by inducing apoptosis, shows growth inhibitory activity against many human tumor cell types in vitro. In humans, 4HPR reduces the incidence of new occurrences of leukoplakia and is currently being tested as a preventive agent for breast cancer. RAG, a naturally occurring metabolite of RA, effectively stimulates the growth of vitamin A- deficient animals, induces the differentiation of epithelial cells in vivo and in vitro, and is effective in the topical treatment of acne in humans. Unlike RA, RAG is nontoxic when applied to the skin and is nonteratogenic when given orally to rats. Possible mechanisms of action of both compounds are discussed. These two derivatives of retinoids show interesting physiologic effects and potentially beneficial pharmacologic actions.

This article has been cited by other articles:

				N. Colombo, F. Formelli, M. G. Cantu, G. Parma, M. Gasco, A. Argusti, A. Santinelli, R. Montironi, E. Cavadini, L. Baglietto, et al. A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1914 - 1919. [Abstract] [Full Text] [PDF]

				M. G. Villani, V. Appierto, E. Cavadini, A. Bettiga, A. Prinetti, M. Clagett-Dame, R. W. Curley, and F. Formelli 4-Oxo-Fenretinide, a Recently Identified Fenretinide Metabolite, Induces Marked G2-M Cell Cycle Arrest and Apoptosis in Fenretinide-Sensitive and Fenretinide-Resistant Cell Lines. Cancer Res., March 15, 2006; 66(6): 3238 - 3247. [Abstract] [Full Text] [PDF]

				M. M. Simile, G. Pagnan, F. Pastorino, C. Brignole, M. R. De Miglio, M. R. Muroni, G. Asara, M. Frau, M. A. Seddaiu, D. F. Calvisi, et al. Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-{kappa}B and Mat1A genes in the early stages of rat liver carcinogenesis Carcinogenesis, February 1, 2005; 26(2): 417 - 427. [Abstract] [Full Text] [PDF]

				M. G. Villani, V. Appierto, E. Cavadini, M. Valsecchi, S. Sonnino, R. W. Curley, and F. Formelli Identification of the Fenretinide Metabolite 4-Oxo-Fenretinide Present in Human Plasma and Formed in Human Ovarian Carcinoma Cells through Induction of Cytochrome P450 26A1 Clin. Cancer Res., September 15, 2004; 10(18): 6265 - 6275. [Abstract] [Full Text] [PDF]

				A. C. Ross and R. Zolfaghari Regulation of Hepatic Retinol Metabolism: Perspectives from Studies on Vitamin A Status J. Nutr., January 1, 2004; 134(1): 269S - 275. [Abstract] [Full Text] [PDF]

				A. Garaventa, R. Luksch, M. S. L. Piccolo, E. Cavadini, P. G. Montaldo, M. R. Pizzitola, L. Boni, M. Ponzoni, A. Decensi, B. D. Bernardi, et al. Phase I Trial and Pharmacokinetics of Fenretinide in Children with Neuroblastoma Clin. Cancer Res., June 1, 2003; 9(6): 2032 - 2039. [Abstract] [Full Text] [PDF]

				A. Prinetti, L. Basso, V. Appierto, M. G. Villani, M. Valsecchi, N. Loberto, S. Prioni, V. Chigorno, E. Cavadini, F. Formelli, et al. Altered Sphingolipid Metabolism in N-(4-Hydroxyphenyl)- retinamide-resistant A2780 Human Ovarian Carcinoma Cells J. Biol. Chem., February 14, 2003; 278(8): 5574 - 5583. [Abstract] [Full Text] [PDF]

				F. Formelli, T. Camerini, E. Cavadini, V. Appierto, M. G. Villani, A. Costa, G. De Palo, M. G. Di Mauro, and U. Veronesi Fenretinide Breast Cancer Prevention Trial: Drug and Retinol Plasma Levels in Relation to Age and Disease Outcome Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 34 - 41. [Abstract] [Full Text] [PDF]

				C. Zou, A.-T. Vlastos, L. Yang, J. Wang, M. Brewer, and M. Follen Effect of 4-Hydroxyphenylretinamide on Human Cervical Epithelial and Cancer Cell Lines Reproductive Sciences, January 1, 2003; 10(1): 41 - 48. [Abstract] [PDF]

				S. A. Gestl, M. D. Green, D. A. Shearer, E. Frauenhoffer, T. R. Tephly, and J. Weisz Expression of UGT2B7, a UDP-Glucuronosyltransferase Implicated in the Metabolism of 4-Hydroxyestrone and All-Trans Retinoic Acid, in Normal Human Breast Parenchyma and in Invasive and in Situ Breast Cancers Am. J. Pathol., April 1, 2002; 160(4): 1467 - 1479. [Abstract] [Full Text] [PDF]

				S. Bruno, C. Tenca, D. Saverino, E. Ciccone, and C. E. Grossi Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment Carcinogenesis, March 1, 2002; 23(3): 447 - 456. [Abstract] [Full Text] [PDF]

				K.-R. You, J. Wen, S.-T. Lee, and D.-G. Kim Cytochrome c Oxidase Subunit III. A MOLECULAR MARKER FOR N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED OXIDATIVE STRESS IN HEPATOMA CELLS J. Biol. Chem., February 1, 2002; 277(6): 3870 - 3877. [Abstract] [Full Text] [PDF]

				N. Hail Jr. and R. Lotan Mitochondrial Respiration Is Uniquely Associated with the Prooxidant and Apoptotic Effects of N-(4-Hydroxyphenyl)retinamide J. Biol. Chem., November 30, 2001; 276(49): 45614 - 45621. [Abstract] [Full Text] [PDF]

				M. Follen, E. N. Atkinson, D. Schottenfeld, A. Malpica, L. West, S. Lippman, C. Zou, W. N. Hittelman, R. Lotan, and W. K. Hong A Randomized Clinical Trial of 4-Hydroxyphenylretinamide for High-Grade Squamous Intraepithelial Lesions of the Cervix Clin. Cancer Res., November 1, 2001; 7(11): 3356 - 3365. [Abstract] [Full Text] [PDF]

				G. R. Benoit, M. Flexor, F. Besancon, L. Altucci, A. Rossin, J. Hillion, Z. Balajthy, L. Legres, E. Segal-Bendirdjian, H. Gronemeyer, et al. Autonomous Rexinoid Death Signaling Is Suppressed by Converging Signaling Pathways in Immature Leukemia Cells Mol. Endocrinol., July 1, 2001; 15(7): 1154 - 1169. [Abstract] [Full Text] [PDF]

				S.-Y. Sun, P. Yue, G. J. Kelloff, V. E. Steele, S. M. Lippman, W. K. Hong, and R. Lotan Identification of Retinamides That Are More Potent than N-(4-Hydroxyphenyl)retinamide in Inhibiting Growth and Inducing Apoptosis of Human Head and Neck and Lung Cancer Cells Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 595 - 601. [Abstract] [Full Text] [PDF]

				N. Hail Jr. and R. Lotan Mitochondrial Permeability Transition Is a Central Coordinating Event in N-(4-Hydroxyphenyl)retinamide-induced Apoptosis Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1293 - 1301. [Abstract] [Full Text]

				J. M. Kurie, J. S. Lee, F. R. Khuri, L. Mao, R. C. Morice, J. J. Lee, G. L. Walsh, A. Broxson, S. M. Lippman, J. Y. Ro, et al. N-(4-Hydroxyphenyl)Retinamide in the Chemoprevention of Squamous Metaplasia and Dysplasia of the Bronchial Epithelium Clin. Cancer Res., August 1, 2000; 6(8): 2973 - 2979. [Abstract] [Full Text]

				K. C. Lewis and J. F. Hochadel Retinoid Metabolism in the Prostate: Effects of Administration of the Synthetic Retinoid N-(4-Hydroxyphenyl)retinamide Cancer Res., December 1, 1999; 59(23): 5947 - 5955. [Abstract] [Full Text] [PDF]

				Y. Chen, J. Buck, and F. Derguini Anhydroretinol Induces Oxidative Stress and Cell Death Cancer Res., August 1, 1999; 59(16): 3985 - 3990. [Abstract] [Full Text] [PDF]

				J. L. Clifford, D. G. Menter, M. Wang, R. Lotan, and S. M. Lippman Retinoid Receptor-dependent and -independent Effects of N-(4-Hydroxyphenyl)retinamide in F9 Embryonal Carcinoma Cells Cancer Res., January 1, 1999; 59(1): 14 - 18. [Abstract] [Full Text] [PDF]

				P. Goyette, C. Feng Chen, W. Wang, F. Seguin, and D. Lohnes Characterization of Retinoic Acid Receptor-deficient Keratinocytes J. Biol. Chem., May 26, 2000; 275(22): 16497 - 16505. [Abstract] [Full Text] [PDF]